

Hepatobiliary and Pancreas Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



LOCOREGIONAL	FIRST LINE	SECOND LINE	THIRD LINE
<u>UCI 19-49</u> Cabo + Ipi/Nivo + TACE Coord: H. Nguyen Accrual: 19/35	<u>UCI 22-106</u> STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab (Slot request required) Coord: H. Nguyen Accrual: 8/10		
<u>UCI 23-75/ROUTE 90</u> Eye90 microspheres Coord: M. Duron Accrual: 2/15	<u>UCI 22-211</u> MED1572 (IgG1 mAb) ± Bev Slot request required Coord: C. Kang Accrual: 3/8	<u>UCI 16-94</u> TATE + Nivolumab (includes gastric/GEJ) Coord: S. Duong Accrual: 29/40	
	<u>UCI 23-104</u> Livmoniplimab + Budigalimab Atezolizumab + Bevacizumab Tremelimumab + Durvalumab Suspended until Q4 2025 Coord: S. Duong Accrual: 3/7	<u>UCI 23-215</u> AZD5851 (GPC3 Autologous CAR-T) Central testing for GPC3 Coord: J. Balague Accrual: 0/5	
	<u>UCI 23-86</u> Atezolizumab ± Bevacizumab (Child-Pugh B7 and B8) Coord: M. Duron Accrual: 0/10		



Open to Accrual
 Low Accruing
 Pending Activation/Suspended

SYSTEMIC + OPERATIVE

ETCTN 10608
Gemcitabine + Cisplatin +
Durva Neo/Adjuvant for high-risk resectable ICC

Coord: H. Nguyen
Accrual: 2/3

UCI 23-99
Randomize, adjuvant
Rilvegostomig/placebo +
capecitabine or gem/cisplatin
after BTC resection

Coord: H. Nguyen
Accrual: 0/8

FIRST LINE

UCI 22-212
(includes Ampullary)

Durvalumab + any
gemcitabine-based regimen
LIMITED SLOTS

Coord: H. Nguyen
Accrual: 5/8

UCI 22-211
MED1572 (IgG1 mAb) or
AZD2936 (TIGIT) ±
gemcitabine and cisplatin

**TBD more slots to be
released**

Coord: C. Kang
Accrual: 1/8


SECOND LINE+

ETCTN-10276
M3814 ± Avelumab +
Hypofraction Radiation

Coord: C. Kang
Accrual: 3/5

UCI 23-200
AZD0901 (CLND18 ADC)
Central prescreening

Coord: C. Kang
Accrual: 4/10





ADJUVANT

[S2104](#)
 Capecitabine + Temozolomide
 vs observation

Pancreatic NET Ki67 > 3%

Coord: J. Balangue
 Accrual: 0/2

SECOND LINE

[ETCTN 10479](#)
 Lu-177 + Sunitinib

Well or moderately
 differentiated PNET
 Up to one line of systemic
 therapy not including
 somatostatin

Coord: H. Nguyen
 Accrual: 0/3

SECOND LINE+

[ETCTN 10558](#)
 Lu-177 ± Triapine

NET w/positive 68 or 64
 DOTATATE on scans

Coord: H. Nguyen
 Accrual: 0/3

Mutation based studies allowing Pancreatic, HCC, and Biliary cancers + other solid tumors

Open to Accrual

Low Accruing

Pending Activation/Suspended

HER2

UCI 20-67
DF1001 +/- nivolumab

Coord: M. Nguyen
Accrual: 18/20

TISSUE FACTOR

UCI 21-146
MRG004A (TF ADC)

Coord: M. Duron
Accrual: 5/11

KRAS/NRAS

UCI 21-53
LY3537982 (KRAS G12C Inhibitor)

Coord: J. Choe
Accrual: 7/8

GERMLINE MUTATIONS

ETCTN-10528
Novobiocin (POLθ)
Germline mutations

Coord: H. Nguyen
Accrual: 0/5

CLAUDIN 18.2

UCI 22-51
ASP2138 (CLDN18.2 BiTe)

Pancreatic and Gastric/GEJ

Coord: P. Yang
Accrual: 18/20

EpCAM

UCI 23-85
BA3182 (CAB T-cell:
EpCAM)

All solid tumors (central
EPCAM testing)

Coord: H. Nguyen
Accrual: 0/3

UCI 22-87
RMC-6236 (KRAS Inhibitor)

Pancreatic KRAS WT 2L

Coord: C. Kang
Accrual: 21/25

UCI 24-82
NRAS, KRAS, BRAF
mutations

Local testing; contact CRC
for specific tumor types

Coord: C. Kang
Accrual: 1/10

GERM/SOMATIC MUTATIONS

UCI 23-162
IMP1734 (PARP1)

PDAC Cohort 1A: BRCA1/2,
PALB2, RAD51B/C/D

Coord: J. Balangue

EGFR

UCI 22-171
EGFR TriNKET +/- Nivolumab
(Central testing)

Coord: M. Nguyen
Accrual: 4/15

Various solid tumors included, or have progressed on, exhausted all therapies, or not amenable to further treatment

UCI 22-26

CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Coord: M. Duron

Accrual: 10/12

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

BLOOD COLLECTION

UCI 21-124

ctDNA collection during HBP
workup

Coord: J. Balague
Accrual: 14/17

UCI 23-10/PRECEDE

(Blood collection for early
detection of pancreatic
cancer)

Pending budget/contract